{"entity":{"type":"insider","cik":"0001626808","url":"/insider/0001626808","json_url":"/insider/0001626808.json","name":"Slawin Kevin M.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":11,"first":"2015-07-17","last":"2017-02-09","span_basis":"filed_date"},"name_variants":[{"name":"Slawin Kevin M.","source":"filing","n_filings":11,"first_seen":"2015-07-17","last_seen":"2017-02-09"}],"transactions":[{"id":4427849,"accession":"0001358403-17-000032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001358403-17-000032","line_url":"/filing/0001358403-17-000032#line-1","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":12.5405,"price_display":"12.54","price_state":"stated","total_value":376215.0,"total_display":"376,215.00","total_whole":"376,215","shares_owned_after":294982.0,"shares_owned_after_display":"294,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-02-07","filed_date":"2017-02-09","scope":"insider"},{"id":2853501,"accession":"0001358403-16-000309","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001358403-16-000309","line_url":"/filing/0001358403-16-000309#line-1","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":15.4513,"price_display":"15.45","price_state":"stated","total_value":463539.0,"total_display":"463,539.00","total_whole":"463,539","shares_owned_after":324982.0,"shares_owned_after_display":"324,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-12-15","filed_date":"2016-12-19","scope":"insider"},{"id":2975257,"accession":"0001358403-16-000273","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001358403-16-000273","line_url":"/filing/0001358403-16-000273","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23216.0,"shares_display":"23,216","price_per_share":20.11886733287388,"price_display":"20.12","price_state":"stated","total_value":467079.624,"total_display":"467,079.62","total_whole":"467,080","shares_owned_after":354982.0,"shares_owned_after_display":"354,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-23","filed_date":"2016-09-23","scope":"insider","n_lines":2},{"id":2975251,"accession":"0001358403-16-000273","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001358403-16-000273","line_url":"/filing/0001358403-16-000273","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":20.04,"price_display":"20.04","price_state":"stated","total_value":4008.0,"total_display":"4,008.00","total_whole":"4,008","shares_owned_after":366940.0,"shares_owned_after_display":"366,940","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-09-21","filed_date":"2016-09-23","scope":"insider","n_lines":2},{"id":2337491,"accession":"0001358403-16-000263","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001358403-16-000263","line_url":"/filing/0001358403-16-000263","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":8000.0,"total_display":"8,000.00","total_whole":"8,000","shares_owned_after":95564.0,"shares_owned_after_display":"95,564","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-20","filed_date":"2016-09-20","scope":"insider","n_lines":2},{"id":2337481,"accession":"0001358403-16-000263","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001358403-16-000263","line_url":"/filing/0001358403-16-000263","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2606.0,"shares_display":"2,606","price_per_share":20.012657329240216,"price_display":"20.01","price_state":"stated","total_value":52152.985,"total_display":"52,152.98","total_whole":"52,153","shares_owned_after":95864.0,"shares_owned_after_display":"95,864","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-19","filed_date":"2016-09-20","scope":"insider","n_lines":2},{"id":2337468,"accession":"0001358403-16-000263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001358403-16-000263","line_url":"/filing/0001358403-16-000263","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1578.0,"shares_display":"1,578","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":31560.0,"total_display":"31,560.00","total_whole":"31,560","shares_owned_after":97264.0,"shares_owned_after_display":"97,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-16","filed_date":"2016-09-20","scope":"insider","n_lines":2},{"id":2486955,"accession":"0001358403-16-000255","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001358403-16-000255","line_url":"/filing/0001358403-16-000255","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67000.0,"shares_display":"67,000","price_per_share":19.31258357313433,"price_display":"19.31","price_state":"stated","total_value":1293943.0994,"total_display":"1,293,943.10","total_whole":"1,293,943","shares_owned_after":100079.0,"shares_owned_after_display":"100,079","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-15","filed_date":"2016-08-17","scope":"insider","n_lines":4},{"id":3057713,"accession":"0001358403-16-000239","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001358403-16-000239","line_url":"/filing/0001358403-16-000239#line-1","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":225000.0,"total_display":"225,000.00","total_whole":"225,000","shares_owned_after":399982.0,"shares_owned_after_display":"399,982","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-27","filed_date":"2016-07-29","scope":"insider"},{"id":3057708,"accession":"0001358403-16-000233","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001358403-16-000233","line_url":"/filing/0001358403-16-000233#line-1","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2719.0,"shares_display":"2,719","price_per_share":13.9919,"price_display":"13.99","price_state":"stated","total_value":38043.9761,"total_display":"38,043.98","total_whole":"38,044","shares_owned_after":134206.0,"shares_owned_after_display":"134,206","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-18","filed_date":"2016-07-19","scope":"insider"},{"id":2897090,"accession":"0001358403-16-000231","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001358403-16-000231","line_url":"/filing/0001358403-16-000231#line-1","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22281.0,"shares_display":"22,281","price_per_share":13.7192,"price_display":"13.72","price_state":"stated","total_value":305677.4952,"total_display":"305,677.50","total_whole":"305,677","shares_owned_after":136925.0,"shares_owned_after_display":"136,925","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-15","filed_date":"2016-07-19","scope":"insider"},{"id":3145482,"accession":"0001358403-16-000166","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001358403-16-000166","line_url":"/filing/0001358403-16-000166","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55000.0,"shares_display":"55,000","price_per_share":11.427242909090909,"price_display":"11.43","price_state":"stated","total_value":628498.36,"total_display":"628,498.36","total_whole":"628,498","shares_owned_after":415182.0,"shares_owned_after_display":"415,182","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-04-22","filed_date":"2016-04-26","scope":"insider","n_lines":3},{"id":8335518,"accession":"0001358403-15-000095","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001358403-15-000095","line_url":"/filing/0001358403-15-000095","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24000.0,"shares_display":"24,000","price_per_share":20.6462,"price_display":"20.65","price_state":"stated","total_value":495508.8,"total_display":"495,508.80","total_whole":"495,509","shares_owned_after":444981.0,"shares_owned_after_display":"444,981","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-11-16","filed_date":"2015-11-18","scope":"insider","n_lines":3},{"id":8870995,"accession":"0001358403-15-000057","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001358403-15-000057","line_url":"/filing/0001358403-15-000057","is_derivative":false,"issuer_cik":"0001358403","issuer_name":"BELLICUM PHARMACEUTICALS, INC","issuer_ticker":"BLCM","issuer_name_source":null,"issuer_url":"/issuer/0001358403","owner_cik":"0001626808","owner_name":"Slawin Kevin M.","owner_display_name":"Slawin Kevin M.","owner_url":"/insider/0001626808","role":"Director, Officer (Chief Technology Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Technology Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":120000.0,"total_display":"120,000.00","total_whole":"120,000","shares_owned_after":458981.0,"shares_owned_after_display":"458,981","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-07-15","filed_date":"2015-07-17","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":28,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001358403","name":"BELLICUM PHARMACEUTICALS, INC","url":"/issuer/0001358403","role":"Director, Officer (Chief Technology Officer)","n_filings":11,"first_seen":"2015-07-17","last_seen":"2017-02-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001626808","retrieved_at":"2026-08-25T14:02:59+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}